Virotherapy using Myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells

Eric Bartee, Amy Meacham, Elizabeth Wise, Christopher R. Cogle, Douglas McFadden

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Graft-versus-host disease (GVHD) is a potentially lethal clinical complication arising from the transfer of alloreactive T lymphocytes into immunocompromised recipients. Despite conventional methods of T cell depletion, GVHD remains a major challenge in allogeneic hematopoietic cell transplant. Here, we demonstrate a novel method of preventing GVHD by ex vivo treatment of primary human hematopoietic cell sources with myxoma virus, a rabbit specific poxvirus currently under development for oncolytic virotherapy. This pretreatment dramatically increases post-transplant survival of immunocompromised mice injected with primary human bone marrow or peripheral blood cells and prevents the expansion of human CD3+ lymphocytes in major recipient organs. Similar viral treatment also prevents human-human mixed alloreactive T lymphocyte reactions in vitro. Our data suggest that ex vivo virotherapy with myxoma virus can be a simple and effective method for preventing GVHD following infusion of hematopoietic products containing alloreactive T lymphocytes such as: allogeneic hematopoietic stem and progenitor cells, donor leukocyte infusions and blood transfusions.

Original languageEnglish (US)
Article numbere43298
JournalPLoS One
Volume7
Issue number8
DOIs
StatePublished - Aug 14 2012
Externally publishedYes

Fingerprint

Myxoma virus
Transplantation (surgical)
xenotransplantation
T-cells
Graft vs Host Disease
Hematopoietic Stem Cells
Stem cells
Viruses
Grafts
Transplantation
Transplants
T-lymphocytes
T-Lymphocytes
Blood
Cells
Oncolytic Virotherapy
Leukocyte Transfusion
Poxviridae
Lymphocytes
blood transfusion

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Virotherapy using Myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells. / Bartee, Eric; Meacham, Amy; Wise, Elizabeth; Cogle, Christopher R.; McFadden, Douglas.

In: PLoS One, Vol. 7, No. 8, e43298, 14.08.2012.

Research output: Contribution to journalArticle

@article{845c63d3ba9243bf8435c50489838770,
title = "Virotherapy using Myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells",
abstract = "Graft-versus-host disease (GVHD) is a potentially lethal clinical complication arising from the transfer of alloreactive T lymphocytes into immunocompromised recipients. Despite conventional methods of T cell depletion, GVHD remains a major challenge in allogeneic hematopoietic cell transplant. Here, we demonstrate a novel method of preventing GVHD by ex vivo treatment of primary human hematopoietic cell sources with myxoma virus, a rabbit specific poxvirus currently under development for oncolytic virotherapy. This pretreatment dramatically increases post-transplant survival of immunocompromised mice injected with primary human bone marrow or peripheral blood cells and prevents the expansion of human CD3+ lymphocytes in major recipient organs. Similar viral treatment also prevents human-human mixed alloreactive T lymphocyte reactions in vitro. Our data suggest that ex vivo virotherapy with myxoma virus can be a simple and effective method for preventing GVHD following infusion of hematopoietic products containing alloreactive T lymphocytes such as: allogeneic hematopoietic stem and progenitor cells, donor leukocyte infusions and blood transfusions.",
author = "Eric Bartee and Amy Meacham and Elizabeth Wise and Cogle, {Christopher R.} and Douglas McFadden",
year = "2012",
month = "8",
day = "14",
doi = "10.1371/journal.pone.0043298",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Virotherapy using Myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells

AU - Bartee, Eric

AU - Meacham, Amy

AU - Wise, Elizabeth

AU - Cogle, Christopher R.

AU - McFadden, Douglas

PY - 2012/8/14

Y1 - 2012/8/14

N2 - Graft-versus-host disease (GVHD) is a potentially lethal clinical complication arising from the transfer of alloreactive T lymphocytes into immunocompromised recipients. Despite conventional methods of T cell depletion, GVHD remains a major challenge in allogeneic hematopoietic cell transplant. Here, we demonstrate a novel method of preventing GVHD by ex vivo treatment of primary human hematopoietic cell sources with myxoma virus, a rabbit specific poxvirus currently under development for oncolytic virotherapy. This pretreatment dramatically increases post-transplant survival of immunocompromised mice injected with primary human bone marrow or peripheral blood cells and prevents the expansion of human CD3+ lymphocytes in major recipient organs. Similar viral treatment also prevents human-human mixed alloreactive T lymphocyte reactions in vitro. Our data suggest that ex vivo virotherapy with myxoma virus can be a simple and effective method for preventing GVHD following infusion of hematopoietic products containing alloreactive T lymphocytes such as: allogeneic hematopoietic stem and progenitor cells, donor leukocyte infusions and blood transfusions.

AB - Graft-versus-host disease (GVHD) is a potentially lethal clinical complication arising from the transfer of alloreactive T lymphocytes into immunocompromised recipients. Despite conventional methods of T cell depletion, GVHD remains a major challenge in allogeneic hematopoietic cell transplant. Here, we demonstrate a novel method of preventing GVHD by ex vivo treatment of primary human hematopoietic cell sources with myxoma virus, a rabbit specific poxvirus currently under development for oncolytic virotherapy. This pretreatment dramatically increases post-transplant survival of immunocompromised mice injected with primary human bone marrow or peripheral blood cells and prevents the expansion of human CD3+ lymphocytes in major recipient organs. Similar viral treatment also prevents human-human mixed alloreactive T lymphocyte reactions in vitro. Our data suggest that ex vivo virotherapy with myxoma virus can be a simple and effective method for preventing GVHD following infusion of hematopoietic products containing alloreactive T lymphocytes such as: allogeneic hematopoietic stem and progenitor cells, donor leukocyte infusions and blood transfusions.

UR - http://www.scopus.com/inward/record.url?scp=84865052411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865052411&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0043298

DO - 10.1371/journal.pone.0043298

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e43298

ER -